Skip to main content

Canadian police officer was 'awkward' helping FBI to extradite Huawei CFO

VANCOUVER (Reuters) - On the day Huawei Chief Financial Officer Meng Wanzhou was detained two years ago, a police officer stationed at Vancouver airport testified on Monday that he found himself in a very uncomfortable position" as the U.S. point of contact. Federal Investigation Bureau (FBI).

As part of her U.S. extradition case, Meng, 48, returned to the British Columbia Supreme Court on Monday for the final week of witness cross examinations, in the wake of reports last week that her lawyers and the U.S. prosecutors held talks to negotiate an arrangement that could see her release and return to China.

I'm not there at the end of the day to provide information and act on behalf of the FBI. I'm employed as an RCMP officer there,' testified Sergeant Ross Lundie of the Royal Canadian Mounted Police (RCMP).

"Given my background, assisting the FBI - this is a very uncomfortable position to be in," he said.

On a warrant from the United States, Meng was arrested in December 2018. She is facing bank fraud charges for allegedly misleading HSBC Holdings Plc about the business activities of Huawei Technologies Co Ltd in Iran, causing the bank to breach U.S. sanctions.

She has said that she is innocent and is fighting extradition from Vancouver under house arrest. Her attorneys have argued that during her investigation and detention, her extradition should be thrown out based on violations of procedure, including improper communication between U.S. and Canadian authorities.

They also argued that the case was politicized to the extent that Meng will not get a fair trial in the United States, referring to remarks made by President Donald Trump in a December 2018 interview with Reuters regarding his ability to use Meng in trade talks with China as a bargaining chip.

A person familiar with the matter said on Thursday, U.S. prosecutors are negotiating an arrangement with attorneys for Huawei's Meng to settle criminal proceedings against her, signaling a possible end to a case that has strained relations between the United States, China and Canada.

Lundie testified two weeks ago that during Meng's investigation and detention, he received at least two calls from FBI officials.

He also told the court in previous testimony that, despite a strong suggestion to the contrary from headquarters, the Canada Border Services Agency (CBSA) should be permitted to perform its review of Meng first.

Lundie testified on Monday that he was worried about the emergence of coordination between the CBSA and the RCMP leading up to the arrest of Meng. Before the RCMP detained her, he told the court it was "reasonable" for CBSA to secure Meng's electronic devices in Mylar bags - which block all signals.

Lundie denied that CBSA's move blurred the lines between the investigation of the RCMP and CBSA since the devices were never searched. "Lundie said, "I saw it as being fair. "With those phones, nothing else was going on."

In previous weeks of cross-examination of witnesses, CBSA and RCMP officials testified that the procedure leading to the investigation and arrest of Meng was hurried, but by the book.

Prosecutors contend that the extradition of Meng is legitimate and protocols have been followed.

The arrest of Meng triggered a chill in Ottawa and Beijing's diplomatic relations. Shortly after Meng was arrested, two Canadian men - Michael Kovrig and Michael Spavor - were arrested by China, who are now facing charges of espionage.

Canadian Prime Minister Justin Trudeau on Friday said his "top priority" was the release of the two Canadians, while refusing to comment on the talks to release Meng.

The case of Meng is planned to wrap up in April 2021.

Comments

Popular posts from this blog

The CEO of AstraZeneca plans to conduct the latest global COVID-19 vaccine trial: Bloomberg

(Reuters) - An additional global trial to test the effectiveness of its COVID-19 vaccine using a lower dose is likely to be conducted by AstraZeneca, its chief executive was quoted as saying on Thursday amid concerns about the outcome of its late-stage review. AstraZeneca could start a new study to test a lower dose of its vaccine that worked better than a full dosage, Pascal Soriot told Bloomberg News, instead of adding the trial to an existing U.S. phase. "We have to validate this now that we have discovered what looks like a better efficacy, so we need to do an additional study," he said, adding that the latest, likely global, study could be quicker because it would require less subjects as the effectiveness was already established to be high. The news comes as AstraZeneca faces concerns about its success rate that some analysts claim could impede its chances of securing rapid regulatory approval from the U.S. and EU. Several scientists have raised concerns about the r

In 'challenging point' Brexit trade negotiations, British minister says

LONDON (Reuters) - Brexit trade negotiations are in a difficult process, and only if the European Union understands that Britain is a sovereign nation will an agreement be reached, said Business Secretary Alok Sharma. "We're at a critical stage," Sky TV told Sharma. "It is fair to say that we are in a difficult phase, that there are still some difficult problems to solve." "We have always said right from the beginning of this process that only if the EU recognizes that the UK is a sovereign independent nation can an agreement be reached," Sharma said. "It is on the basis of that a deal will be done."

AstraZeneca to purchase Alexion to grow in immunology for $39 billion

FRANKFURT (Reuters) -Britain's AstraZeneca has agreed to buy U.S. drugmaker Alexion Pharmaceuticals in the biggest transaction ever for $39 billion, diversifying its fast-growing cancer sector in a gamble on medicines for rare diseases and immunology. The deal comes a week after AstraZeneca said it was undertaking more testing to confirm whether its COVID-19 vaccine could be 90% successful, potentially delaying its introduction, and was introduced in Britain as a competing shot from Pfizer and approved for use in the United States . On Saturday, the British company said Alexion shareholders will receive $60 in cash and around $115 worth of equity per share - either in ordinary shares exchanged in the UK by AstraZeneca or in American Depositary Shares denominated in dollars. That implies a total price of $175 per share based on a reference average ADR price of $54.14. Alexion shares closed on Friday at about $121 apiece. "It's a tremendous opportunity for us to accelera